scientifyRESEARCH
research funding database

RESEARCH FUNDING

Collaborative Research Development Grant – AI (ovarian cancer worldwide)

Share this post

Logo of scientifyRESEARCH and Enago "Author First, Quality First" scientifyRESEARCH recommends English editing and author support services from Enago.
Text on a blue background says "Want to find funding & get support for grant-writing?" Logos of scientifyRESEARCH & GrantDesk appear below on a white background and an orange play symbol appears between the two logos. An arrow mark points to the logos.

The Collaborative Research Development Grant-AI funded by Ovarian Cancer Research Alliance (OCRA) together with Microsoft AI for Health supports interdisciplinary research teams that leverage AI to advance ovarian cancer research. Submissions may be on screening and early detection, etiology and prevention, molecular therapeutics, cancer biology and genetics. Proposals that focus on health services research, quality of life, and epidemiology are also encouraged. All investigators/collaborators must hold full-time faculty appointments in a school of medicine or public health or recognized non-profit scientific research facility. International collaborations are welcome. Applicants may apply for up to 300,000 USD per year for up to 3 years (including 10% indirect costs). Investigators funded through this grant opportunity have access to support from Microsoft in the form of Azure computing credits, and in-kind data science support.

Letters of intent are due on March 27, 2024 and full applications close on June 13, 2024.

Read more about OCRA at our Funder Perspectives blog series.

Adverts. Premium members do not see Google Ads.

Please Login / Subscribe to our premium membership to see the content. Sign up to Free trial to see detailed funding information.

non member

We value your opinion

Complete our 1-min user survey and receive complimentary full access to our premium research funding database.

Sign-up for our monthly
research funding newsletter

you can unsubscribe at any time